Agios’ oral drug secures PhIII success in transfusion-independent thalassemia patients

Ayisha Sharma

News Reporter

Agios Pharmaceuticals’ oral drug candidate is a step closer to market after it succeeded in a late-stage study in thalassemia patients who don’t need regular …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Agios’ oral drug secures PhIII success in transfusion-independent thalassemia patients

Ayisha Sharma

News Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Agios’ oral drug se­cures PhI­II suc­cess in trans­fu­sion-in­de­pen­dent tha­lassemia pa­tients

Ayisha Sharma

News Reporter

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Agios’ oral drug secures PhIII success in transfusion-independent thalassemia patients

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?